SCHEMBL7515875

SCHEMBL7515875

Cc1ccccc1NC(=O)NC1=CC(=O)SC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.54
ALDH1A1 P00352 4/20 0.54
TP53 P04637 2/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
HSD17B10 Q99714 2/20 0.54
GAA P10253 1/20 0.54
ALOX15 P16050 1/20 0.54
DDX3X O00571 2/20 0.50
POLB P06746 3/20 0.48
RAB9A P51151 6/20 0.47
NPC1 O15118 6/20 0.47
NPSR1 Q6W5P4 1/20 0.47
HPGD P15428 2/20 0.46
ITGB3 P05106 2/20 0.46
ITGAV P06756 2/20 0.46
ITGB1 P05556 1/20 0.46
ITGA5 P08648 1/20 0.46
HTT P42858 3/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7518356 0.83 HTT (0.54) MAPTALDH1A1GAARAB9ANPC1
SCHEMBL7524876 0.83 NPC1 (0.60) MAPTGAAPOLBRAB9ANPC1
SCHEMBL7524755 0.79 SMN1; SMN2 (0.55) MAPTTP53RAB9ANPC1NPSR1
SCHEMBL7521172 0.78 LMNA (0.57) MAPTALDH1A1L3MBTL1HSD17B10GAA
SCHEMBL1275926 0.78 RAB9A (0.75) MAPTALDH1A1TP53L3MBTL1HSD17B10
SCHEMBL8210609 0.77 RAB9A (0.50) MAPTALDH1A1TP53L3MBTL1HSD17B10
SCHEMBL7521744 0.74 RAB9A (0.50) MAPTALDH1A1TP53L3MBTL1HSD17B10
SCHEMBL7522011 0.74 GAA (0.52) MAPTALDH1A1TP53L3MBTL1HSD17B10
SCHEMBL7525033 0.73 RAB9A (0.56) MAPTALDH1A1L3MBTL1GAARAB9A
SCHEMBL8369698 0.72 ALDH1A1 (0.76) MAPTALDH1A1TP53L3MBTL1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020058694-A1 Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents ROCHE DIAGNOSTICS GMBH 2002-05-16 US disclosed
US-6333346-B1 AMINOFURANONEUREAS OR THIOUREAS 4-AMINO-2(5H)-THIOPHENONES AS ANTITUMOR AGENTS ROCHE DIAGNOSTICS GMBH (DE) 2001-12-25 US disclosed
EP-1009747-A1 UREIDO AND THIOUREIDO DERIVATIVES OF 4-AMINO-2(5H)-FURANONES AND 4-AMINO-2(5H)-THIOPHENONES AS ANTITUMOR AGENTS Roche Diagnostics GmbH (DE) 2000-06-21 EP disclosed
WO-1999012917-A1 UREIDO AND THIOUREIDO DERIVATIVES OF 4-AMINO-2(5H)-FURANONES AND 4-AMINO-2(5H)-THIOPHENONES AS ANTITUMOR AGENTS ROCHE DIAGNOSTICS GMBH (DE) 1999-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020058694-A1 Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents UTS2R, SRD5A2, SRD5A1 MAPT 4634/4885ALDH1A1 223/4885TP53 1739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.